Reynolds DS[au] - Search Results

Year	Number of Results
1981	1
1986	1
1987	1
1988	2
1989	2
1990	3
1991	4
1992	2
1993	1
1996	1
1997	1
1998	3
2000	1
2001	3
2002	1
2003	3
2004	7
2005	6
2006	9
2007	2
2008	4
2009	1
2010	5
2011	1
2012	1
2013	1
2014	3
2015	1
2016	2
2017	2
2018	5
2019	3
2021	2

1

Impact of the physical microenvironment on tumor progression and metastasis.

Spill F, Reynolds DS, Kamm RD, Zaman MH. Spill F, et al. Among authors: reynolds ds. Curr Opin Biotechnol. 2016 Aug;40:41-48. doi: 10.1016/j.copbio.2016.02.007. Epub 2016 Mar 2. Curr Opin Biotechnol. 2016. PMID: 26938687 Free PMC article. Review.

2

A short perspective on the long road to effective treatments for Alzheimer's disease.

Reynolds DS. Reynolds DS. Br J Pharmacol. 2019 Sep;176(18):3636-3648. doi: 10.1111/bph.14581. Epub 2019 Mar 1. Br J Pharmacol. 2019. PMID: 30657599 Free PMC article. Review.

3

Thomas H. Kunz.

Richardson CS, Hood W, Allen L, Hristov N, Ineson K, Reichard J, McCracken G, Kurta A, Reynolds DS. Richardson CS, et al. Among authors: reynolds ds. Physiol Biochem Zool. 2021 Jul-Aug;94(4):253-267. doi: 10.1086/714937. Physiol Biochem Zool. 2021. PMID: 34096823 No abstract available.

4

Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases.

Benn CL, Gibson KR, Reynolds DS. Benn CL, et al. Among authors: reynolds ds. J Huntingtons Dis. 2021;10(1):203-220. doi: 10.3233/JHD-200421. J Huntingtons Dis. 2021. PMID: 32925081 Free PMC article. Review.

5

Endophthalmitis after penetrating ocular trauma.

Reynolds DS, Flynn HW Jr. Reynolds DS, et al. Curr Opin Ophthalmol. 1997 Jun;8(3):32-8. doi: 10.1097/00055735-199706000-00006. Curr Opin Ophthalmol. 1997. PMID: 10168892 Review.

6

Designing drugs for the treatment of female sexual dysfunction.

Brown AD, Blagg J, Reynolds DS. Brown AD, et al. Among authors: reynolds ds. Drug Discov Today. 2007 Sep;12(17-18):757-66. doi: 10.1016/j.drudis.2007.07.007. Epub 2007 Aug 27. Drug Discov Today. 2007. PMID: 17826689 Review.

7

Photosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator.

Gurrell R, Gorman D, Whitlock M, Ogden A, Reynolds DS, DiVentura B, Abou-Khalil B, Gelfand M, Pollard J, Hogan RE, Krauss G, Sperling M, Vazquez B, Wechsler RT, Friedman D, Butt RP, French J. Gurrell R, et al. Among authors: reynolds ds. Neurology. 2019 Apr 9;92(15):e1786-e1795. doi: 10.1212/WNL.0000000000007271. Epub 2019 Mar 15. Neurology. 2019. PMID: 30877186 Clinical Trial.

8

Design and Identification of a Novel, Functionally Subtype Selective GABA_A Positive Allosteric Modulator (PF-06372865).

Owen RM, Blakemore D, Cao L, Flanagan N, Fish R, Gibson KR, Gurrell R, Huh CW, Kammonen J, Mortimer-Cassen E, Nickolls SA, Omoto K, Owen D, Pike A, Pryde DC, Reynolds DS, Roeloffs R, Rose C, Stead C, Takeuchi M, Warmus JS, Watson C. Owen RM, et al. Among authors: reynolds ds. J Med Chem. 2019 Jun 27;62(12):5773-5796. doi: 10.1021/acs.jmedchem.9b00322. Epub 2019 Apr 26. J Med Chem. 2019. PMID: 30964988

9

Differentiating the role of gamma-aminobutyric acid type A (GABAA) receptor subtypes.

Wafford KA, Macaulay AJ, Fradley R, O'Meara GF, Reynolds DS, Rosahl TW. Wafford KA, et al. Among authors: reynolds ds. Biochem Soc Trans. 2004 Jun;32(Pt3):553-6. doi: 10.1042/BST0320553. Biochem Soc Trans. 2004. PMID: 15157182 Review.

10

Effects of drugs that potentiate GABA on extinction of positively-reinforced operant behaviour.

Leslie JC, Shaw D, McCabe C, Reynolds DS, Dawson GR. Leslie JC, et al. Among authors: reynolds ds. Neurosci Biobehav Rev. 2004 May;28(3):229-38. doi: 10.1016/j.neubiorev.2004.01.003. Neurosci Biobehav Rev. 2004. PMID: 15225968 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results